Xurodopa 125 Tablet combines Levodopa 100mg with Carbidopa 25mg, a potent therapy for Parkinson’s disease. Levodopa increases dopamine levels in the brain to improve motor function, while Carbidopa enhances its effectiveness and minimizes side effects such as nausea and vomiting.
This combination belongs to the neurology and CNS segment and is prescribed for managing tremors, rigidity, bradykinesia, and other Parkinsonian symptoms. The higher Carbidopa dose in this formulation ensures better Levodopa availability and improved patient outcomes.
Xurodopa 125 is widely used in long-term Parkinson’s management, offering flexibility for dose adjustments according to patient response. Its consistent efficacy makes it a high-demand product across hospitals, neurology clinics, and specialty pharmacies.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Xurodopa 125 Tablet provides a profitable B2B opportunity in the anti-Parkinson segment with steady demand and significant growth potential across India.
Nausea, vomiting, dizziness, headache, low blood pressure, sleep disturbances, and involuntary movements (dyskinesia). Rarely, it may cause hallucinations, severe mood changes, or heart rhythm abnormalities.
Used in the treatment of Parkinson’s disease and parkinsonian symptoms. It helps control tremors, rigidity, bradykinesia, and enhances overall mobility and daily functioning.
Take Xurodopa 125 Tablet exactly as prescribed, preferably at the same time each day. Do not stop suddenly, as this may worsen symptoms. Inform your doctor if you have heart disease, liver or kidney issues, or psychiatric disorders.
Store below 25°C in a cool, dry place away from sunlight and moisture. Keep out of reach of children.